Biotech entity
All 1 tracked stories fall under one category: clinical-trial. Ocular Therapeutix, Inc. is most often covered alongside Bayer Aktiengesellschaft, which appears in 1 of these 1 story. Each carries 28 original sources on average. We currently track 1 Biotech story that mention Ocular Therapeutix, Inc., all published on February 18, 2026.
Last mentioned: Feb 20, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: clinical-trial. Ocular Therapeutix, Inc. is most often covered alongside Bayer Aktiengesellschaft, which appears in 1 of these 1 story. Each carries 28 original sources on average. We currently track 1 Biotech story that mention Ocular Therapeutix, Inc., all published on February 18, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 13 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Ocular Therapeutix, Inc.. Shared-story counts are live from our verified record — not editorial picks.
Genmab A/S reported a decline in full-year profits, marking a period of significant financial and clinical divergence across the biotechnology sector. While breakthrough results in depression therapy propelled Compass Pathways, Ocular Therapeutix suffered a sharp decline despite meeting Phase 3 trial endpoints.
Ocular Therapeutix, Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
